ArticleClinical kidney journal2025
The predictive value of TG/HDL and TC/HDL for risk of mortality and cardiovascular events in incident peritoneal dialysis patients.
Article in Clinical kidney journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study investigated the association between triglyceride/high-density lipoprotein cholesterol (TG/HDL-C), total cholesterol/high-density lipoprotein cholesterol (TC/HDL-C) and clinical outcomes in patients with peritoneal dialysis (PD) through the present prospective cohort study. Methods: This study is an observational analysis based on PD Telemedicine-assisted Platform Cohort Study. The lipid data was defined as the average levels for the first 3 months after receiving PD, including TG, TG and HDL-C. The primary outcome was all-cause mortality, and the secondary outcomes were major adverse cardiovascular events (MACE), modified MACE+ and hemodialysis transfer. Results: A total of 5875 PD patients were enrolled. By cubic spline regression analysis, the cut-off value of TG/HDL-C and TC/HDL-C were 1.25 and 4.20, respectively. During the follow-up time, 1098 (7.75/100 person-years) patients died, and the leading cause of mortality was cardiovascular diseases [686 (4.85/100 person-years)]. MACE and modified MACE+ occurred in 845 (6.09/100 person-years) and 1459 (10.83/100 person-years) patients, respectively. There were 719 patients (5.08/100 person-years) transferred to hemodialysis. The incidence of all-cause mortality, MACE and modified MACE+ were significant higher in groups with elevated TG/HDL-C and TC/HDL-C ( Conclusions: Among patients treated with PD, the elevated TG/HDL-C and TC/HDL-C were independently associated with increased risk of mortality and cardiovascular events.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.